GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

eptinezumab   Click here for help

GtoPdb Ligand ID: 10694

Synonyms: ALD-403 | ALD403 | eptinezumab-jjmr | Vyepti®
Approved drug
eptinezumab is an approved drug (FDA (2020), EMA (2022))
Compound class: Antibody
Comment: Eptinezumab is a humanized IgG1 anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the prevention of migraine [6]. It was developed by Lundbeck and their subsidiary Alder Biopharmaceuticals (Alderbio). The INN record for eptinezumab indicates that it binds to CALCA (α-CGRP) and CALCB (β-CGRP). Peptide sequence alignment using NCBI BLAST Protein reveals 100% matches with sequences claimed in Alderbio's patent WO2012162257A2, and distinguish eptinezumab as the monoclonal referred to as Ab5 in the patent document.

CGRP plays an important role in migraine pathophysiology [2], and both the CGRP peptide and its receptor (CGRPR) are targets of anti-migraine therapeutics [1,4-5]. Eptinezumab is the fourth anti-CGRP pathway monoclonal to reach the clinic: the others are erenumab (anti-CGRPR), galcanezumab (anti-CALCA/B) and fremanezumab (anti-CALCA/B). These antibodies are used as alternatives to CGRPR antagonists such as ubrogepant (FDA approved in 2019).
Classification Click here for help
Compound class Antibody
Approved drug? Yes. EU EMA (2022)  |  US FDA (2020)
International Nonproprietary Names Click here for help
INN number INN
10308 eptinezumab
Synonyms Click here for help
ALD-403 | ALD403 | eptinezumab-jjmr | Vyepti®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 648
Other databases
GtoPdb PubChem SID 404859141
Search PubMed clinical trials eptinezumab
Search PubMed titles eptinezumab
Search PubMed titles/abstracts eptinezumab